Plavix Sales Measures Complicated By Inconsistencies With IMS Data – BMS
Executive Summary
"Significant" variability in the prescription volume data reported by market researcher IMS Health has prompted Bristol-Myers Squibb to revise the way it tracks the performance of its anti-clotting drug Plavix (clopidogrel) in recent months